Ivonescimab clinical trials

Explore recruiting ivonescimab clinical trials.

Recruiting ivonescimab studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ivonescimab trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)

France, Spain, Ireland, Greece, Germany, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)

France, Spain, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Germany, Italy, Spain, France, Ireland, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

France, Poland, Ireland, Spain, Greece, Germany +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

Belgium, Italy, Spain, Germany, France, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

GRACIE : Phase II study evaluating ivonescimab in combination with chemotherapy for first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Ivonescimab trials by city

Ivonescimab in Toronto Ivonescimab in Vancouver Ivonescimab in Montreal Ivonescimab in Calgary Ivonescimab in Edmonton Ivonescimab in Ottawa Ivonescimab in Winnipeg Ivonescimab in Quebec City Ivonescimab in Hamilton Ivonescimab in Kitchener Ivonescimab in London Ivonescimab in Halifax Ivonescimab in New York Ivonescimab in Los Angeles Ivonescimab in Chicago Ivonescimab in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease